Knight Therapeutics (TSE:GUD) had its target price boosted by TD Securities from C$9.50 to C$10.00 in a report published on Friday morning.

Several other analysts have also issued reports on GUD. Raymond James set a C$10.25 price target on shares of Knight Therapeutics and gave the stock an outperform rating in a research report on Thursday, July 12th. Beacon Securities reaffirmed a buy rating on shares of Knight Therapeutics in a research report on Thursday, April 26th. Cormark reaffirmed a buy rating and set a C$10.50 price target on shares of Knight Therapeutics in a research report on Friday, May 11th. Finally, Royal Bank of Canada reiterated an outperform rating and issued a C$9.50 price objective on shares of Knight Therapeutics in a report on Monday, April 23rd. Five equities research analysts have rated the stock with a buy rating, The stock has a consensus rating of Buy and an average target price of C$10.15.

Knight Therapeutics opened at C$8.33 on Friday, according to Marketbeat. Knight Therapeutics has a 1 year low of C$7.38 and a 1 year high of C$9.11.

Knight Therapeutics (TSE:GUD) last posted its quarterly earnings results on Thursday, May 10th. The company reported C$0.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of C$0.03 by C$0.02. The firm had revenue of C$3.15 million for the quarter, compared to the consensus estimate of C$1.76 million.

In other Knight Therapeutics news, Director Meir Jakobsohn sold 10,000 shares of the company’s stock in a transaction on Thursday, May 24th. The shares were sold at an average price of C$8.16, for a total value of C$81,600.00. Over the last quarter, insiders sold 52,100 shares of company stock worth $421,174.

About Knight Therapeutics

Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.

Featured Article: Diversification Important in Investing

Analyst Recommendations for Knight Therapeutics (TSE:GUD)

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with's FREE daily email newsletter.